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Abstract
Background: The incidence of acute kidney injury (AKI) has been increasing over time and is associated with a
high risk of short-term death. Previous studies on hospital-acquired AKI have important methodological limitations,
especially their retrospective study designs and limited ability to control for potential confounding factors.
Methods: The Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study
was established to examine how a hospitalized episode of AKI independently affects the risk of chronic kidney
disease development and progression, cardiovascular events, death, and other important patient-centered
outcomes. This prospective study will enroll a cohort of 1100 adult participants with a broad range of AKI and
matched hospitalized participants without AKI at three Clinical Research Centers, as well as 100 children
undergoing cardiac surgery at three Clinical Research Centers. Participants will be followed for up to four years,
and will undergo serial evaluation during the index hospitalization, at three months post-hospitalization, and at
annual clinic visits, with telephone interviews occurring during the intervening six-month intervals. Biospecimens
will be collected at each visit, along with information on lifestyle behaviors, quality of life and functional status,
cognitive function, receipt of therapies, interim renal and cardiovascular events, electrocardiography and urinalysis.
Conclusions: ASSESS-AKI will characterize the short-term and long-term natural history of AKI, evaluate the
incremental utility of novel blood and urine biomarkers to refine the diagnosis and prognosis of AKI, and identify a
subset of high-risk patients who could be targeted for future clinical trials to improve outcomes after AKI.
Background
As currently defined, acute kidney injury (AKI) refers to
a sudden decrease in kidney function as measured by
changes in serum creatinine concentration and/or urine
output. This phenomenon has been best studied among
hospitalized patients and is associated with a high risk
(>30%) of short-term mortality in severe cases [1]. The
importance of AKI as a clinical and public health pro-
blem is underscored by recent studies showing a rising
incidence in the U.S. over the past several decades [2,3].
The vast majority of published studies on AKI have
focused primarily on clinical outcomes that occur dur-
ing the index hospitalization complicated by AKI [4-8].
In 2005, the American Society of Nephrology Renal
Research Report listed as a “critically important knowl-
edge gap” studies addressing “long-term outcomes” after
an episode of AKI [1]. Recently, several studies have
attempted to examine the impact of hospital-acquired
AKI on longer-term outcomes, including the risk of
development and acceleration of chronic kidney disease
(CKD), end-stage renal disease (ESRD), and death
[9-14]. However, many existing studies have important
methodological challenges that hamper their ability to
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outcomes. These include retrospective study designs,
suboptimal quantification of severity of baseline CKD
and severity of AKI, ascertainment of clinical outcomes
based on data collected as part of routine clinical care
and limited ascertainment of important confounding
variables. Consequently, there has been a growing
appreciation of the need to more rigorously address this
question.
In 2007, the National Institute of Diabetes, Digestive
and Kidney Diseases (NIDDK) released an Request For
Applications (DK-07-009 “Ancillary Studies in the Nat-
ural History of Acute Kidney Injury”)t oc r e a t eam u l t i -
center research consortium to address these knowledge
gaps by expanding our understanding of the natural his-
tory of patients suffering from AKI. The Assessment,
Serial Evaluation and Subsequent Sequelae of Acute
Kidney Injury (ASSSESS-AKI) Consortium was estab-
lished in 2008 to compare prospectively differences in
the occurrence of renal and cardiovascular outcomes
and death within a diverse, matched cohort of patients
with and without AKI. The overall goals of ASSESS-AKI
are to:
￿ Establish a diverse prospective, parallel, matched
cohort of adults and children with and without AKI.
￿ Characterize the short-term and long-term natural
history of AKI based on current serum creatinine-
based diagnostic criteria.
￿ Evaluate the incremental utility of novel blood and
urine biomarkers to refine the diagnosis and prog-
nosis of AKI.
￿ Develop a prognostic risk model that integrates
patient characteristics and biomarkers to help inform
providers and patients about the risks of adverse
events after an episode of AKI.
￿ Identify the subset of high-risk patients who could
be targeted for future interventional clinical trials to
improve outcomes after an episode of AKI.
The ASSESS-AKI Study will leverage ongoing studies
involving patients undergoing cardiac surgery or in the
intensive care unit and expand the study population to
include a more general hospitalized population to pro-
vide a broadly representative study of the natural history
of AKI.
Methods
Study organization
The ASSESS-AKI Study consists of a Data Coordinating
Center (Pennsylvania State University), three Clinical
Research Center networks through Kaiser Permanente
Northern California (Oakland, CA; San Francisco, CA;
Walnut Creek, CA), Vanderbilt University (Nashville,
TN), and the Translational Research Investigating Bio-
marker Endpoints in Acute Kidney Injury (TRIBE-AKI)
network (New Haven, CT; Cincinnati, OH; London,
Ontario; Montreal, Quebec). A central laboratory for
analysis of core biochemistries is located at the Univer-
sity of Minnesota and an electrocardiography reading
center is based at Wake Forest University (Figure 1). In
addition, ASSESS-AKI includes an External Advisory
Committee and NIDDK project scientists.
The Institutional Review Boards of the Data Coordi-
nating Center and participating Clinical Research Cen-
ters’ institutions approved the study.
Study design
ASSESS-AKI will employ a parallel, matched, prospec-
tive cohort design of adult participants with and without
AKI. In addition, ASSESS-AKI will attempt to enroll
and prospectively follow all eligible children undergoing
cardiac surgery requiring cardiopulmonary bypass who
are participants in the TRIBE-AKI Consortium study.
The study will enroll 1200 participants (1100 adults, 100
children) with approximately 50% of adult participants
having AKI and the remaining 50% representing
matched adult participants without AKI. Scheduled fol-
low-up visits for each participant will occur during the
subsequent four years. Informed consent will be
obtained in all patients in accordance with the principles
of the Declaration of Helsinki.
Clinical research center networks
Participating Clinical Research Center Networks have
active research programs related to AKI and the consor-
tium is leveraging their existing research expertise,
resources and infrastructure to establish the prospective,
multi-center ASSESS-AKI cohort.
Kaiser Permanente Northern California
Kaiser Permanente of Northern California in collabora-
tion with the University of California, San Francisco has
been conducting a series of NIDDK-sponsored
(U01DK060902, R01DK067126, R01DK058411) longitu-
dinal studies characterizing the epidemiology and out-
comes of acute, chronic, and end-stage renal disease
within Kaiser Permanente’s large and diverse commu-
nity-based population in the San Francisco and greater
Bay area. Kaiser Permanente is one of the largest inte-
grated health care delivery systems in the U.S and pro-
vides comprehensive care for >3.2 million members that
are ethnically and socioeconomically diverse and highly
representative of the northern California and statewide
population. Kaiser delivers comprehensive inpatient and
outpatient care to its members through 18 hospitals and
>60 additional ambulatory medical offices and captures
many aspects of its care through the use of its compre-
hensive clinical (e.g., inpatient and outpatient laboratory
Go et al. BMC Nephrology 2010, 11:22
http://www.biomedcentral.com/1471-2369/11/22
Page 2 of 13tests) and administrative (e.g., diagnoses, procedures,
mortality) databases, which will be leveraged for
ASSESS-AKI. The Kaiser Permanente Division of
Research will lead recruitment and enrollment of parti-
cipants hospitalized in medical and surgical wards as
well as intensive care units (ICU) at three Kaiser Perma-
nente Medical Centers located in Oakland, San Fran-
cisco and Walnut Creek.
Vanderbilt University
Vanderbilt University Medical Center (VUMC) is a large
tertiary referral center serving the middle Tennessee
area and surrounding region and provides comprehen-
sive acute and critical care services. ASSESS-AKI inves-
tigators are primarily leveraging the ongoing National
Heart, Lung and Blood Institute (NHLBI)-funded
(U01HL081332)-sponsored Validation of Acute Lung
Injury Biomarkers for Diagnosis (VALID) Study. VALID
is a single-center, prospective study whose purpose is to
develop and validate a panel of diagnostic and prognos-
t i cp l a s m aa n d / o ru r i n eb i o m a r k e r si nad i v e r s ec o h o r t
of 2550 critically ill patients at high risk for developing
ALI/ARDS as well as AKI [15]. All adult (≥18 years)
patients admitted to one of four ICUs at VUMC who
remained in the ICU at day 2 were eligible for enroll-
ment. Patients are excluded if they experienced a cardiac
arrest before enrollment, had transfer orders written or
anticipated within 4 hours, died or were discharged
within 48 hours of ICU admission, were admitted for
uncomplicated overdose, were in the ICU for >3 days
before enrollment, or who had chronic lung disease
requiring oxygen supplementation or pulmonary fibro-
sis. Per parent study protocol, blood and urine samples
are currently collected at study enrollment on ICU day
2 and subsequent sampling on ICU day 4. In addition to
VALID subjects, VUMC investigators are recruiting
additional subjects from the same VALID ICUs as well
as neurologic and burn ICUs who meet inclusion cri-
teria for VALID.
TRIBE-AKI
TRIBE-AKI is an ongoing prospective cohort study of
more than 1800 adults and children sponsored by the
NHLBI (R01HL085757) whose goal is to validate
selected biomarkers for the diagnosis and risk stratifica-
tion of AKI after cardiac surgery (coronary artery bypass
Figure 1 Organizational structure for the ASSESS-AKI Study. NIDDK = National Institute of Diabetes, Digestive and Kidney Diseases; DCC =
Data Coordinating Center; CRC = Clinical Research Center network; and ECG = electrocardiography
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Page 3 of 13and/or valvular repair or replacement). Patients are
excluded if they had any of the following: pre-operative
AKI (≥0.5 mg/dL increase in serum creatinine concen-
tration from preadmission to initiation of cardiac sur-
gery); pre-operative end-stage renal disease (serum
creatinine level ≥4.5 mg/dL [400 μmol/L] receiving
chronic dialysis or prior renal transplant), prior cardiac
transplant or insertion of left ventricular assist device;
receipt of nephrotoxic agents within 48 hours preceding
cardiac surgery, or acute infective endocarditis. Pediatric
participants are limited to those requiring cardiopul-
monary bypass. TRIBE-AKI participants have compre-
hensive clinical data, blood and urine samples collected
pre-operatively as well as from the first five post-
operative days. ASSESS-AKI will include a subset of
TRIBE-AKI sites: Yale University, London Health Sciences
Center (Ontario), University of Cincinnati Children’sH o s -
pital, and Montreal Children’sH o s p i t a l( Q u e b e c ) .
Cohort participants
T h eA S S E S S - A K IS t u d yw i l le n r o l lad i v e r s eg r o u po f
adults (age 18 to 89 years) and children (age one month
to 18 years) with and without AKI from participating
Clinical Research Center networks.
Baseline kidney function
To participate, all patients must have an available baseline
pre-admission serum creatinine value, which is then used
to estimate glomerular filtration rate (eGFR). A baseline
serum creatinine value is defined as the outpatient, non-
emergency department test result nearest to the index
hospitalization. For the Kaiser Permanente and VALID
Clinical Research Centers, the nearest value between 7
and 365 days before admission will be used, while for the
TRIBE-AKI Clinical Research Center, the baseline serum
creatinine can be present between 1 and 365 days before
surgery, provided the patient is undergoing elective sur-
gery. The rationale for this approach is based on prelimin-
ary data from the three Clinical Research Center networks
demonstrating that the vast majority of potentially eligible
participants do not have more than two to three pre-
admission serum creatinine values during this time frame
and that the most recent value is more likely to reflect the
subject’s “baseline” kidney function before the index hospi-
talization. All serum creatinine results must be performed
using an isotope dilution mass spectrometry (IDMS)-
traceable serum creatinine assay.
Exclusion criteria
Exclusion criteria were selected to balance the goal of
maximizing representativeness of the cohort, clinical
accuracy of AKI, and feasibility in achieving the project
goals. These criteria are detailed in Table 1. The data
sources used to ascertain information on these criteria
include electronic and paper medical records, other
electronic databases, and patient interviews.
Definition of AKI
We recognize the limitations of the most recently pro-
posed definitions for AKI (i.e., RIFLE [16] and Acute Kid-
ney Injury Network [AKIN] [17]), which are based only on
changes in serum creatinine concentration and/or urine
output. However, despite enthusiasm for potentially more
sensitive and specific novel serum and urine biomarkers,
[18] to date, none have been sufficiently validated as better
measures of AKI or of subsequent prognosis than serum
creatinine-based AKI criteria. A major goal of ASSESS-
AKI is to provide key insights into the prognostic value of
novel AKI biomarkers. Therefore, AKI will be operationa-
lized as follows which is anticipated to capture a broad
spectrum of kidney injury. For adult participants, AKI will
be defined as ≥50% relative increase and/or absolute
increase ≥0.3 mg/dL (26 μmol/L) in peak inpatient serum
creatinine compared with baseline outpatient serum crea-
tinine. For pediatric participants, AKI will be defined as
≥50% relative increase in peak inpatient serum creatinine
compared with baseline serum creatinine. We did not
incorporate urine output criteria from the AKIN classifica-
tion scheme because of concern about the systematic
availability and quality of data about urine output, espe-
cially in non-ICU patients who are unlikely to have
indwelling urinary catheters. Furthermore, incorporating
the urine output criteria for AKIN might overly enrich our
cohort for patients with pre-renal azotemia.
To enhance the likelihood of enrolling an adequate
number of adult participants with more severe AKI, we
have set an enrollment target of at least one third of AKI
participants having ≥100% relative increase in serum crea-
tinine. To increase the probability of having an adequate
number of adult participants with AKI due to causes other
than rapidly reversible pre-renal azotemia, we have set an
enrollment target of at least one third of AKI participants
who meet AKI criteria lasting ≥48 hours. These additional
enrollment targets are not mutually exclusive, and we
anticipate significant overlap in these pre-specified sub-
groups. Furthermore, study nephrologists at each partici-
pating site will review selected index hospitalization
information to classify each enrolled AKI case into one of
the following presumptive categories: acute tubular necro-
sis (ATN), pre-renal azotemia, and other/unknown.
Definition of absence of AKI
Subjects will be considered not to have AKI if they meet
the following criteria. For adult participants, non-AKI
status will be defined as having both <20% relative
increase and an absolute increase ≤0.2 mg/dL (18 μmol/
L) in peak inpatient serum creatinine compared with
baseline outpatient serum creatinine. For pediatric parti-
cipants, non-AKI status will be defined as <50% relative
increase in peak inpatient serum creatinine compared
with baseline serum creatinine.
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Page 4 of 13Initial screening and enrollment of participants
Subject recruitment will vary by participating site and
among adult versus pediatric participants, in accor-
dance with requirements of local institutional review
boards’ guidelines and the requirements of sites within
each Clinical Research Center network. As described
above, all pediatric patients undergoing cardiac surgery
requiring cardiopulmonary bypass at the two pediatric
TRIBE-AKI sites will be screened for enrollment into
ASSESS-AKI. Enrollment of ASSESS-AKI pediatric par-
ticipants will occur post-operatively during the index
hospitalization. During this first inpatient visit of
enrolled children, baseline clinical data and quality of
life questionnaires will be administered and 1 blood
and urine specimen obtained within the first four post-
operative days will be stored for future biomarker
testing.
Among adult participants, we will enroll a parallel
matched cohort of patients with and without AKI (Fig-
ure 2). Adult patients with AKI will be identified during
the index hospitalization and screened for initial eligibil-
ity. During this inpatient visit, enrolled AKI patients will
undergo urinalysis with microscopy through the hospital
clinical laboratory and provide at least one sample of
blood and urine for future biomarker testing within 96
hours of the episode of AKI.
Given the matched parallel cohort design, we will iden-
tify and enroll a sample of hospitalized adult patients
who did not appear to suffer an AKI episode and who are
matched in a minimum 1:1 AKI:non-AKI ratio, with each
non-AKI subject individually matched to their corre-
sponding AKI subject on the following set of key con-
founding characteristics: Clinical Research Center and
presence of baseline chronic kidney disease using an
CKD-EPI [19] equation-estimated GFR threshold of <60
ml/min/1.73 m
2. In addition, we will further attempt to
match on the presence or absence of clinical cardiovascu-
lar disease, presence or absence of diabetes mellitus, cate-
gory of baseline eGFR (15-29, 30-44, 45-59, 60-89, 90-
150 ml/min/1.73 m
2), adult age category (18-39, 40-49,
Table 1 Inclusion and exclusion criteria for the ASSESS-AKI Study
Inclusion criteria Exclusion Criteria
Adult participants aged 18 years to 89 years. Inability to provide informed or surrogate consent.
Children aged greater than one month to less than 18 years old at
cohort entry.
Died prior to the three-month study visit.
Documented “baseline” serum creatinine defined as the outpatient, non-
emergency department test value nearest to the index hospitalization
within 7 and 365 days prior to admission using an IDMS-traceable serum
creatinine assay.
Incarcerated, institutionalized, or otherwise unable to participate in the
study within a home, community, or clinical setting.
In the TRIBE-AKI consortium, pre-operative serum creatinine results from
an IDMS-traceable assay obtained within seven days before cardiac
surgery can be used to define “baseline” kidney function for the subset
of participants who are undergoing non-urgent cardiac surgery.
Enrolled in an active interventional study at the three-month in-person
study visit.
For pediatric participants in TRIBE-AKI, a pre-operative serum creatinine
concentration measured in the local hospital clinical laboratory among
patients scheduled for elective cardiac surgery.
Actively pregnant or breastfeeding. Prior chronic hemodialysis, peritoneal
dialysis (lasting ≥three months), or estimated GFR <15 ml/min/1.73 m2
not receiving renal replacement therapy. History of solid organ and/or
hematopoietic cell transplants.
Acute glomerulonephritis diagnosed clinically or by biopsy.
Clinically significant urinary tract obstruction, confirmed by imaging.
Hospitalization involving acute nephrectomy.
History of multiple myeloma.
Hepatorenal syndrome.
Metastatic cancer or systemic cancer receiving active treatment.
New York Heart Association Class IV heart failure prior to index admission.
Predicted survival of 12 months or less as determined by the participant’s
treating physician or Clinical Research.
Center Principal Investigator.
AKI participants who remain hospitalized 90 or more days after the AKI
episode.
ESRD at the time of the three-month study visit.
Unable to provide at least 1.5 mL of plasma for adults at the Inpatient
visit.
Unable to provide at least 3 mL of urine for adults at the Inpatient visit.
Unable to provide at least 10 mL of blood for adults and 1 mL of blood
for children at the three-month visit.
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Page 5 of 1350-59, 60-69, 70-79, 80-89 years), and hospital location
where AKI episode occurred (ICU versus non-ICU).
Follow-up visits and retention strategies
The follow-up visit and contact schedule are summar-
ized in Table 2. All recruited participants will be invited
to an in-person baseline study visit at 3 months after
the AKI episode for AKI participants or 3 months after
hospital discharge for non-AKI participants. Participants
will return annually for in-person follow-up visits. Parti-
cipants will be contacted by telephone at the 6-month
intervals between clinic visits to obtain information on
study events, or updates on general health and contact
information.
Consistent with other cohort studies (e.g., Athero-
sclerosis Risk in Communities Study, [20] Cardiovascu-
lar Health Study [21]), we project that approximately 3
to 5% of participants may be lost to follow-up annually.
Multiple approaches will be used to prevent participant
dropout. The National Death Index will be searched
periodically for all participants lost-to-follow-up to
ensure complete vital status information. We will imple-
ment previously tested retention strategies to promote a
high level of long-term participation. These will include
free medical testing, semi-annual contact with partici-
pants via telephone calls, along with newsletters con-
taining study updates and information about kidney
disease, personalized mailings, and reimbursement of
time and travel expenses.
Collection of study data
At the outpatient visit at 3 months following the index
hospitalization, adult participants will be screened again
for eligibility and eligible persons will have consent
obtained for long-term follow-up (Table 2). Pediatric
participants will have had consent for long-term follow-
up visits obtained during the index hospitalization.
Information will be collected on detailed sociodemo-
graphic information, lifestyle habits, medical and family
history, quality of life, current medication use, quality of
life and functional status (SF-12v2™ Health Survey [22]
in adults, PedsQL Generic and Cardiac modules in chil-
dren), [23] cognitive function (Modified Mini-Mental
Status Examination,[3MS] [24] and Trails B [25]),
anthropometric measures (weight, height), and resting
blood pressure and heart rate. In addition, blood speci-
mens for DNA, sera and plasma as well as a random
urine sample will be obtained for local urine dipstick
Figure 2 Summary of identification and enrollment approach for AKI and Non-AKI participants. The figure applies to adult participants
only. Any eligible pediatric subject undergoing cardiopulmonary bypass-requiring cardiac surgery is approached for participation during the
inpatient phase.
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York, NY). Sera, plasma and urine samples will be col-
lected annually and stored for subsequent measurement
of renal and cardiovascular-related biomarkers related to
multiple pathways involving early AKI. The list of all
the different biological specimen types that are being
collected at each visit and will be stored in the NIDDK
biorepository are given in Table 2.
Biomarkers
A major goal of ASSESS-AKI is to evaluate the utility of
urine and blood biomarkers for improving the diagnosis
and risk stratification after a hospitalized episode of
AKI. Given rapid and ongoing advances in the discovery
of putative novel biomarkers for AKI, [18] the biomar-
kers to be evaluated within ASSESS-AKI will be priori-
tized based on the currently available evidence at the
time of testing. The initial preliminary set of biomarkers
includes those with the strongest clinical evidence base
as markers of early AKI and will be measured in all
study participants. Given the current data supporting
the use of these markers for the detection of AKI, it will
be important to know whether these markers predict
short or long term outcomes. This set will include urine
biomarkers (IL-18, [26] NGAL, [27] KIM-1, [28] cystatin
C ,[ 2 9 ]L - F A B P[ 3 0 ]a n dN A G[ 3 1 ] )a n db l o o db i o m a r -
kers (serum cystatin C, [32] serum NGAL [33] and
plasma IL-6 [34]).
Renal outcomes
Kidney function measurement
The primary renal outcome is the change in kidney
function during follow-up. Kidney function will be
defined before and after an AKI episode (as well as
among those without AKI) using outpatient serum crea-
tinine concentration measurements. Given the known
limitations of using serum creatinine alone as a measure
of kidney function, [35] except for its use in defining an
episode of AKI per the criteria described previously, we
will use the CKD-EPI equation to estimate GFR using
an IDMS-traceable serum creatinine assay among all
adult study participants. For pediatric participants, we
will estimate GFR using the recommended Schwartz for-
mula [36] based on serum creatinine values measured in
local laboratories using the same assays for baseline and
follow-up measurements within those sites. Urine
albuminuria will be measured using a spot albumin-to-
creatinine ratio [37].
Table 2 Summary of visit schedule and study components for the ASSESS-AKI Study
Schedule Inpatient Baseline Year 1 Year 2 Year 3 Year 4
Months 0 3 6 12 18 24 30 36 42 48
Type of Contact Visit Visit Phone Visit Phone Visit Phone Visit Phone Visit
Consent for inpatient visit and specimen collection ●
Consent for long-term follow-up ●
Update contact info ● ● ●●●●●●●●
Inpatient medications ●
Inpatient risk factors for AKI ●
Outcome Events ● ●●●●●●●●
Outpatient medications ● ●●●●●●●●
Urinalysis with microscopy (adults) ●
Urine dipstick (adults) ● ●●●●
Height and weight ● ●●●●
Blood pressure ● ●●●●
Questionnaires
Sociodemographic characteristics ●●
Lifestyle habits ● ●●●●
Medical History ● ●●●●
Quality of life and functional status ● ●●●●
Cognitive function (adults) ●● ●
Electrocardiogram (adults) ● ●●●●
Collect specimens for storage in biorepository ● ● ●●●●
Random urine sample ● ● ●●●●
Blood for DNA ●
Serum ● ●●●●
Plasma-EDTA ● ● ●●●●
Plasma-citrate ● ●●●●
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Among participants without pre-existing CKD at the
index hospitalization, we will examine time to develop-
ment of incident CKD with significant loss of renal
function defined as experiencing both a minimum 25%
reduction in level of eGFR compared with baseline and
achieving CKD Stage 3 or worse [37] during follow-up.
Progression of CKD
Among participants with pre-existing CKD at the index
hospitalization (defined as an eGFR <60 ml/min/1.73 m
2),
we will examine time to progression of CKD, defined as
experiencing at least a 50% reduction in level of eGFR com-
pared with baseline or progressing to CKD Stage 5 [37].
Development of ESRD
Development of ESRD after the 3 month follow-up visit
will be defined as any of the following: (1) peritoneal
dialysis or hemodialysis treatment at least once a week
for at least 12 consecutive weeks, (2) receipt of a kidney
transplant and/or (3) death while receiving dialysis.
Incident or recurrent episodes of AKI
We will attempt to ascertain incident and recurrent epi-
sodes of AKI. Based on available data collected during
follow-up, we will use the same criteria described pre-
viously to define incident (among non-AKI participants)
or recurrent (among AKI participants) episodes of AKI.
However, we recognize that some study participants
may be hospitalized at non-Clinical Research Center
network facilities where complete medical and labora-
tory records may not be readily available (and where
n o n - I D M Ss e r u mc r e a t i n i n ea s s a y sm a yb eu s e d ) ,h i n -
dering accurate determination of whether observed
changes in serum creatinine reflect progression of kid-
ney dysfunction or a new episode of AKI. In such cases,
we will pursue whether the hospitalizations included
administrative diagnostic codes for AKI and acute dialy-
sis treatments which are typically coded administratively
and likely reflect more severe AKI episodes.
Cardiovascular outcomes
To maximize future collaborations with other studies
focused on kidney disease among adult populations, we
have modelled our definitions after those used in the CRIC
Study [38] and various longitudinal studies (Cardiovascular
Health Study, [21] Atherosclerosis Risk in Communities
[20] and Antihypertensive and Lipid Lowering Treatment
to Prevent Heart Attack Trial [39]). The general approach
will be to obtain self-reported and/or site-specific database
information on potential outcome events and subsequently
obtain information on qualifying International Classifica-
tion of Diseases, Ninth and Tenth Editions (ICD-9 and
ICD-10) codes at each site which will facilitate review of
relevant medical records to adjudicate. The following out-
comes are only relevant for the subgroup of adult partici-
pants given that they are extremely rare among children.
Coronary heart disease
Standard definitions will be used to classify a coronary
heart disease event. This includes acute coronary syn-
dromes such as unstable angina, non-ST-elevation
myocardial infarction and ST-elevation myocardial
infarction [40,41]. Myocardial infarction will be further
classified according to recent international consensus
guideline [42]. Sudden cardiac death will be obtained
by mortality files and subject proxy contacts. It will be
defined as either an unwitnessed death without
another obvious cause or death occurring within one
hour of the onset of ischemic symptoms per a proxy
[43]. Silent myocardial infarction will be defined as
new, pathologic Q waves on serial electrocardiograms
(ECG) [44] among the subgroup of enrolled adult par-
ticipants with the event date assigned as the mid-point
between the relevant annual visits. Coronary artery
revascularization will include either percutaneous cor-
onary intervention with or without intracoronary stent-
ing or coronary artery bypass surgery of one or more
coronary blood vessels.
Heart failure
Heart failure will be based on hospitalizations for a clin-
ical heart failure syndrome using relevant discharge
diagnosis codes and confirmed based on Framingham
Heart Study clinical criteria ascertained from medical
records [45]. We will not require evidence of systolic
dysfunction (e.g., left ventricular ejection fraction <40%)
or diastolic dysfunction on echocardiography [46].
Cardiac Arrhythmias and Electrocardiographic
Abnormalities
Arrhythmias and other ECG abnormalities will be based
on serial ECGs using Minnesota Code definitions, [47]
which have been used in epidemiological studies and
have direct clinical applicability. These include develop-
ment of atrial fibrillation, atrial flutter, left and right
bundle branch block, atrioventricular conduction
defects, and left ventricular hypertrophy among others.
Cerebrovascular outcomes
Pertinent cerebrovascular disease outcomes include
ischemic stroke and intracranial hemorrhage, and caro-
tid endarterectomy. Ischemic stroke will be defined as
acute development of a neurological deficit fitting a
vascular distribution, lasting ≥24 hours, and no other
evident etiology such as intracranial hemorrhage, vas-
culitis, tumor, or trauma [48,49]. Intracranial hemor-
rhage will require validation by brain imaging or
pathologic evidence, and should have a documented
history consistent with a stroke syndrome, diminished
consciousness, or headache [50]. Carotid endarterect-
omy will include both surgical endarterectomy and bal-
loon angioplasty with or without carotid stent
placement.
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Outcomes will include aortic aneurysm and lower extre-
mity arterial revascularization or amputation for refractory
ischemia. Lower extremity revascularization will include
both percutaneous peripheral artery angioplasty and surgi-
cal arterial bypass procedures, and lower extremity ampu-
tation will include procedures performed for refractory
ischemia. Hospitalizations for thoracic or abdominal aortic
aneurysm dissection, rupture or repair (using percuta-
neous or surgical procedures) will be included.
Mortality
Deaths will be identified primarily through surveys of
subjects or their proxy contacts and review of medical
records or death certificates, if available. We will also
seek to obtain information on social security number
from participants to conduct probability matches with
Social Security Administration vital status files [51] and
National Death Index [52] among the subset set of par-
ticipants who are lost to follow-up. All-cause mortality
will be the preferred outcome given known significant
errors in assigning etiology [53].
Statistical approach and power
The primary outcomes for the study are time-to-event
outcomes, such as time to death, a renal event or a clini-
cal cardiovascular event. Some of these events will be
known exactly on a continuum and could be right-cen-
sored. Exact dates for the occurrence of some of the
events, however, may only be known to occur within a
specific time interval tk,k=1 ,2 ,3 ,4 ,5( t 1 = 0-3 months,
t2 =3 - 1 2m o n t h s ,t 3 = 12-24 months, t4 = 24-36 months,
t5 =3 6 - 4 8m o n t h s ) .T h ee n d p o i n t so ft h e s ef i v et i m e
intervals correspond to the planned in-person study vis-
its. Therefore, the statistical analyses in these situations
will invoke continuous time-to-event models that
account for right-censored and interval-censored data.
T h eh a z a r df u n c t i o nf o rac o n t i n u o u st i m e - t o - e v e n t
outcome is of the form
λλβ ijk ijk ijk tx t x ( ; ) ( )exp( ) = 0
where
(a) lijk(t; xij) is the hazard function at time t with
covariate vector xijk for the k
th member of the j
th
matched set within the i
th site, j = 1, 2,...,ni,a n dk=
0 (non-AKI), 1 (AKI),
(b) l0(t) is the baseline hazard function,
(c) b is an unknown parameter vector, and
(d) xijk is a vector of regressors of interest.
The regressors that will appear in xijk for the primary
statistical analyses are as follows using as examples
different variables: binary indicator variables at month 0
for non-AKI/AKI status, CKD status, gender, Hispanic
ethnicity, cardiovascular disease status, diabetes status and
sepsis status; ordinal variables at month 0 for racial group
(0 = white/European, 1 = Black/African American, 3 =
Asian/Pacific Islander, 4 = Native American, 5 = Other/
Admixed), eGFR (0 = 15 to 29, 1 = 30 to 44, 2 = 45 to 59,
3 = 60 to 89, 4 = 90-150) and albumin-to-creatinine ratio
(0 = <0.15, 1 = 0.15 to 0.5, 2 = >0.5 to 1.0, 3 = >1.0 to 3.0,
and 4 = >3.0), age (0 = 1 to 17, 1 = 18 to 39, 2 = 40 to 49,
3 = 50 to 59, 4 = 60 to 69, 5 = 70 to 79, 6 = 80 to 89).
The hazard model described above, however, is not
the final form of the hazard model that will be applied
in this study. Instead, the hazard model needs to
account for (1) the dependency between an AKI subject
and a non-AKI subject within a matched pair and (2)
informative censoring. The occurrence of some of the
renal and cardiovascular events may not be independent
of the censoring event of death. For example, individuals
who are censored because of death may have been at
higher risk for renal and cardiovascular events. There-
fore, a bivariate hazard function for the simultaneous
modeling of the renal (or cardiovascular) event and
death is invoked [54,55]. Let (Tijk,D ijk) denote the con-
tinuous time of a renal or cardiovascular event and the
time of death, respectively, for the k
th member of the j
th
pair within the i
th site, j = 1, 2,...,ni, and k = 0 (non-
AKI), 1 (AKI). The bivariate hazard model is
λλβλ λ T,ijk ijk T0 ijk Ti Tij D,ijk ijk tx t x e a n d  dx ( ; ) ( )exp( ) ( ; ) =+ = D D0 ijk Di Dij dx e ( )exp( ) β+
where the [eTij eDij]’s are independent and identically
distributed according to a bivariate normal distribution
with null mean vector and positive-definite variance
matrix. The covariance between eTij and eDij represents
the magnitude of the relationship between the occur-
rence of the renal (or cardiovascular) event and the cen-
soring event of death. An estimated value of the
covariance near zero indicates non-informative censor-
ing, whereas an estimated value of the covariance distant
from zero indicates informative censoring.
T h es a m p l es i z ef o rt h es t u d yi s( 1 )5 5 0a d u l tA K I
subjects and 550 matched adult non-AKI subjects and
(2) 50 pediatric AKI subjects and 50 pediatric non-AKI
subjects, at the 3-month visit. For a two-sided, 0.05 sig-
nificance level test of the relative risk equaling 1.0, the
sample size of 1,200 yields greater than 80% statistical
power, while allowing for a 15% withdrawal rate, for
detecting a relative risk between 1.35 (when the event
rate for AKI subjects is 30%) and 1.90 (when the event
rate for AKI subjects is 10%).
Discussion
Despite the emerging clinical and public health impor-
tance of AKI, studies to date have traditionally focused
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attempts to extend focus on longer-term outcomes have
primarily involved the retrospective study of administra-
tive databases in different population and clinical set-
tings [9-14]. While these studies have reported a link
between AKI and increased risk for either advanced
CKD, [9,14] ESRD, [10-13] and all-cause death,
[9-12,56-59] there have been several important limita-
tions. Specifically, all published studies were retrospec-
tive in nature. Many did not use observed changes in
serum creatinine to define AKI or rigorously quantify
baseline renal function or but rather relied on adminis-
trative diagnostic codes for defining “AKI” and deter-
mining presence or absence of baseline CKD and
potential confounders. Most studies included only a
relatively small number of outcomes. Importantly, none
of the studies collected specimens to measure biomar-
kers both during the AKI admission and after hospital
discharge. The ASSESS-AKI study will address many of
these limitations by establishing a prospective, matched
parallel cohort of persons (including children) with and
without AKI based on serum creatinine-based criteria
measured in a standardized fashion, serial collection of
blood and urine for evaluating of diagnostic and prog-
nostic markers in AKI, and systematic follow-up for
changes in renal function and multiple clinical and
patient-centered outcomes.
One of the key challenges of existing studies relates to
defining “baseline” kidney function for determination
whether an episode of AKI has occurred and the sever-
ity of AKI [60,61]. A recent examination of this issue
revealed that the use of imputed or commonly used sur-
rogate estimates of baseline function can result in sub-
stantial misclassification of AKI and hinder adequate
study of its associated outcomes [62]. Enrollment into
ASSESS-AKI requires a pre-admission serum creatinine
performed using an IDMS-traceable assay using a time
frame recent enough to the index hospitalization that is
likely to represent steady-state renal function and will
substantially reduce the misclassification of the main
exposure (i.e., occurrence of AKI) and of a key confoun-
der (pre-admission CKD status) for enrolled partici-
pants, but it also creates barriers to participant
recruitment. Many hospitalized patients who experience
or are at risk for AKI may not have serum creatinine
values available before the AKI episode, available values
may not be performed using an IDMS-traceable assay,
available values may be outside of our pre-specified time
window (7 to 365 days before the index hospitalization),
or values obtained during the eligible time window may
not actually reflect steady-state renal function. All stu-
dies of AKI are affected by this challenge given that cur-
rently available consensus definitions of AKI are based
on the magnitude of change of serum creatinine
concentration. ASSESS-AKI will have strong internal
validity given that both participants with and without
A K Iw i l lh a v eac o n s i s t e n t l ym e a s u r e db a s e l i n em e a s u r e
of renal function that will serve as an anchor for assess-
ment of longitudinal changes in kidney function.
As patients who suffer from AKI also tend to systema-
tically differ from those without AKI on relevant demo-
graphic and clinical characteristics, accurate assessment
of these variables is paramount to delineating the risk
attributable to AKI for poor outcomes. Toward that
end, existing studies based on their retrospective design
and limited data quality have been susceptible to notable
residual confounding and biases that limit the ability to
delineate the independent contribution of AKI, espe-
cially less severe episodes, on adverse clinical outcomes.
In particular, the use of administrative codes to capture
the primary exposure (AKI) and critically important
modifiers such as underlying CKD can lead to misclassi-
fication bias reflected in a substantial exaggeration or
underestimation of the effect observed. Most studies
also did not control for the presence and severity of
CKD before the AKI episode, which is problematic
g i v e nt h a tC K Da n dC K Ds e v e r i t ya r eb o t hp o t e n tp r e -
dictors of experiencing AKI as well as CKD progression,
ESRD and other adverse outcomes. In addition to using
standardized measurements of serum creatinine in
detailing both AKI and CKD, ASSESS-AKI will also
implement a 1:1 AKI:non-AKI participant matching
algorithm along with advanced analytic methods that
should help to mitigate major confounding for evaluat-
ing the independent impact of AKI on targeted out-
comes of interest during long-term follow-up.
Current efforts to develop and validate diagnostic bio-
markers that can define and predict both AKI and CKD
progression based on absolute levels rather than on
changes from baseline–as is necessary when utilizing
serum creatinine concentrations–may mitigate the chal-
lenges of requiring a standard definition. One of the
major goals of ASSESS-AKI is to evaluate the incremen-
tal utility of blood and urine biomarkers to refine the
diagnosis and prognosis of AKI above current defini-
tions using a prospective serial biospecimen collection
protocol; standardized collection, processing, storage
and testing methodology; and a diverse set of clinical
settings and patients. Most of the recently discovered
putative biomarkers of AKI are known to demonstrate
time-dependent fluctuations around the time of AKI
[18]. Some biomarkers are most elevated within a few
hours after a known insult such as cardiac surgery (e.g.,
NGAL, L-FABP), while other prominent biomarkers
have a delay in their expression, with peak values occur-
ring 24-48 hours after the time of presumed injury (e.g.,
IL-18, KIM-1) [18]. We anticipate that the timing of the
presumed renal insult will vary across the three Clinical
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AKI. The TRIBE-AKI cohort will, in general, experience
injury occurring during or after the time of cardiopul-
monary bypass; the VALID cohort may have multiple
episodes of injury in the setting of critical illness, and
the Kaiser Permanente cohort will have variation in tim-
ing of injury depending on the clinical setting (e.g., med-
ical or surgical wards, oncology or cardiology service)
within a general hospitalized population. Thus, our
approach is tailored to promote generalizability and
pragmatism for biospecimen collection, as both blood
and urine will be collected on the day of or as soon as
possible after the identification of clinical AKI based on
serum creatinine concentration change. Based on this
approach, it remains questionable whether biomarkers
of current interest will be at or near their peak concen-
tration. However, if biomarkers of AKI are to be widely
used by practicing physicians, they are most likely to be
initially used when there is evidence of AKI by standard
diagnostic criteria to improve the diagnosis and/or prog-
nosis of AKI. Therefore, the results from ASSESS-AKI
should be broadly generalizable to clinical practice.
In addition to the challenges mentioned above,
characterizing the type of AKI, which could influence
short- and long-term outcomes, has been relatively
understudied in epidemiologic studies of AKI. Both
AKIN and RIFLE consensus criteria do not encourage
discrimination of the type of AKI (i.e., ATN, pre-renal
azotemia, other), implying that the etiology and type of
AKI do not affect subsequent outcomes after accounting
for the magnitude of change in serum creatinine con-
centration and/or urine output. However, ASSESS-AKI
will prospectively evaluate the contribution of type of
AKI on long-term clinical outcomes -above and beyond
conventional measures of AKI severity. We believe that
attempting to differentiate AKI “phenotype” (i.e., ATN
vs. pre-renal azotemia vs. other) is important to address
this knowledge gap. We also recognize that there cur-
rently exists no “gold standard” method to distinguish
between phenotypes and that the same patient could
have multiple contributing etiologies for AKI. Thus, we
will implement several strategies, including targeted
enrollment of more severe AKI based on greater change
in serum creatinine concentra t i o na n d / o rl o n g e rd u r a -
tion of serum creatinine elevation that is more likely to
represent ATN; urine analysis and microscopy at the
time of AKI for identification of urine sediment consis-
tent with ATN (e.g., granular casts); and standardized
adjudication of cases via consultation notes, discharge
summaries, and other clinical variables. Overall, the
ASSESS-AKI study will provide one of the most com-
prehensive efforts to characterize AKI phenotype and
whether it independently alters the risk of long-term
clinical outcomes.
While ASSESS-AKI has numerous strengths, it also
has several limitations. The cohort will be enriched with
patients suffering AKI in common at-risk settings such
as surrounding cardiac surgery or within the ICU as
well as in more general hospitalized settings, but we will
have limited power to examine whether the clinical set-
ting modifies the association between AKI and clinical
outcomes. The inclusion of children expands the age
range being evaluated but is only applicable to those
requiring cardiopulmonary bypass. The relatively small
number of children targeted for enrollment means we
will be able to detect only large effect sizes. The multi-
center cohort includes various U.S. and Canadian sites
and health care delivery systems, but the results may
not be generalizable to all practice settings and popula-
tions. Despite various design and analytic approaches as
well as standardized data collection and quality control
efforts, as an observational study, we cannot rule out
the impact of residual confounding and bias. However,
since a randomized comparison is not possible, our pro-
spective cohort design and systematic follow-up will
provide a rigorous assessment among eligible partici-
pants. There are ongoing plans to address some of these
limitations by augmenting ASSESS-AKI with possible
ancillary studies (e.g., recruitment of a larger number of
pediatric patients).
Conclusions
Improving our ability to diagnose and risk stratify AKI
and understanding its natural history are pressing public
health issues. The ASSESS-AKI Study is well-positioned
to provide novel insights into these and other areas and
will create a unique longitudinal resource for the
nephrology research community.
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